Menu
Back to Journals » Orthopedic Research and Reviews » Volume 14
Monitoring and Management of Fibrodysplasia Ossificans Progressiva: Current Perspectives [Corrigendum]
Authors Smilde BJ , Botman E, de Ruiter RD, Smit JM, Teunissen BP, Lubbers WD, Schwarte LA, Schober P, Eekhoff EMW
Received 2 May 2022
Accepted for publication 2 May 2022
Published 4 May 2022 Volume 2022:14 Pages 147—148
Smilde BJ, Botman E, de Ruiter RD, et al. Orthop Res Rev. 2022;14:113–120.
On page 118, Treatments in Development section, 2nd paragraph, 2nd sentence “The only drug in development for FOP in this medication class is Palovarotene, a retinoic acid-gamma (RAR-γ) antagonist” should read “The only drug in development for FOP in this medication class is Palovarotene, a retinoic acid-gamma (RAR-γ) agonist”.
The authors affirm that this error does not affect the results, discussion, and conclusions of the reported study and apologize for any inconvenience caused to the readers.
© 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.